6,917 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Callan Family Office LLC

Callan Family Office LLC purchased a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 6,917 shares of the company's stock, valued at approximately $1,127,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC grew its holdings in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares during the period. Darwin Wealth Management LLC acquired a new position in shares of Zoetis in the 3rd quarter valued at $31,000. First Personal Financial Services purchased a new stake in shares of Zoetis during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis during the 3rd quarter valued at $33,000. Finally, Dunhill Financial LLC increased its holdings in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after buying an additional 75 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.16% of the company's stock.

Remove Ads

Zoetis Trading Up 1.8 %

NYSE ZTS traded up $3.09 during trading hours on Friday, hitting $170.34. The company's stock had a trading volume of 3,296,788 shares, compared to its average volume of 3,274,650. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $76.28 billion, a P/E ratio of 31.14, a PEG ratio of 2.78 and a beta of 0.94. The stock has a fifty day moving average of $166.72 and a 200 day moving average of $176.78.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date is Monday, April 21st. Zoetis's payout ratio is presently 36.56%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Barclays lifted their target price on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Piper Sandler boosted their target price on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Leerink Partnrs raised shares of Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday. Finally, Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective for the company. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.